Key Facts & History

The following information shows the summary unaudited pro forma financial information for the combined company.

VRX
Exchange/Ticker

~15,000
Worldwide Employees

Corporate Headquarters
Laval, Quebec, Canada


Revenue

2014 Full Year Revenues: $8.25 billion

2013 Full Year Revenues: $5.76 billion

2012 Full Year Revenues: $3.48 billion

Snapshot

  • Multinational specialty pharmaceutical company

  • Diverse product portfolio with focus on branded pharmaceuticals, branded generics and over-the-counter products

  • Specialization in dermatology, eye health, neurology and consumer healthcare

  • Product sales with focus on North America, Europe and the Middle East, Latin America and Asia Pacific

  • Development capability

  • Manufacturing sites in Canada, Brazil, Poland and Mexico

  • Regulatory and medical expertise

Pipeline Highlights

  • Brimonidine (eye whitener)

  • Vesneo (glaucoma)

  • Lotemax Gel Next Gen (post-operative pain, inflammation)

  • BioTrue Toric (contact lens)              
  • IDP-118 (plaque psoriasis)

History

  • Valeant completes its acquisition of substantially all the assets of Dendreon Corporation, including worldwide rights to PROVENGE®, an immunotherapy treatment for advanced prostate cancer
  • An ad for Jublia, Valeant's onychomycosis treatment, appears on the Super Bowl telecast
  • Valeant acquires Solta Medical which designs, manufactures and markets medical-device systems for aesthetic applications
  • U.S. FDA announces approval of Retin-A Micro® 0.08% for the treatment of acne
  • Valeant agrees to acquire PreCision Dermatology, a move aimed at strengthening Valeant’s skin-products business
  • U.S. FDA announces approval of Jublia® for treatment of onychomycosis
  • U.S. FDA announces approval of Onexton™ Gel for the treatment of acne vulgaris
  • Valeant acquires Natur Produkt International, Russian specialty pharmaceutical company
  • Valeant continues building its aesthetics and dermatology portfolios with the acquisition of Obagi Medical Products
  • Valeant acquires Bausch + Lomb, creating a major player in the eye health segment and expanding its international presence
  • Bausch + Lomb receives U.S. FDA clearance for Ultra™ silicon hydrogel monthly contact lens
  • Health Canada announces approval of Jublia® for treatment of onychomycosis
  • U.S. FDA announces approval of topical anit-fungal Luzu®
  • Valeant moves its global head office to Laval, Quebec, where it establishes a Center of Excellence in Dermatology
  • Valeant enters a new market segment with its acquisition of OraPharma, oral health company
  • Representing a significant step in becoming a leader in dermatology and aesthetics, Valeant acquires Medicis Pharmaceuticals
  • In separate transactions, Valeant acquires assets from Swiss Herbal, University Medical, Gerot Lannach and Atlantis Pharma
  • Valeant expands its European footprint, acquiring Switzerland-based generics company PharmaSwiss, with operations in 19 countries
  • Mike Pearson appointed Chairman of the Board
  • Valeant acquires Lithuania-based AB Sanitas, which specializes in branded generics
  • Valeant acquires Dermik, dermatology unit of Sanofi
  • Valeant acquires the Ortho Dermatologics division of Janssen Pharmaceuticals
  • Valeant acquires Afexa Life Sciences, Canadian health-science company
  • Howard Schiller appointed Chief Financial Officer
  • Valeant further establishes its presence in Australia, Asia Pacific and South Africa with the acquisition of iNova, which sells and distributes OTC and prescription products
  • Two Brazilian pharmaceutical companies focused on branded generics and OTCs are acquired by Valeant.
  • Valeant acquires Aton Pharma, which delivers new platforms in eye health and neurology.
  • Valeant and Biovail agree to merge, creating an international leader in specialty pharmaceuticals. The new company, incorporated in Canada, retains the Valeant name with Mike Pearson serving as CEO.

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • Valeant acquires Dow Pharmaceutical Sciences, which specializes in topical dermatology products and provides an important R&D platform
  • Acanya™ Gel, for treatment of acne, launched by Coria Laboratories
  • Biovail acquires U.S. rights to Wellbutrin XL® for the treatment of seasonal major depressive illness
  • Valeant acquires Tecnofarma, producer of generic pharmaceuticals located in Mexico

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • Valeant names Mike Pearson Chairman and CEO
  • Biovail acquires Prestwick Pharmaceuticals, which holds rights to Xenazine®, first FDA-approved treatment for a Huntington’s disease-related symptom
  • Valeant acquires Coria Laboratories, which specializes in dermatology products
  • Valeant acquires DermaTech, Australian company focused on dermatology products

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • Valeant launches Bedoyecta, a brand of vitamin B complex products, in the U.S.
  • Wellbutrin XR™ receives its first European approval

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • Biovail receives approval for Wellbutrin XL® to treat depression in Canada
  • Valeant expands its Kinerase® professional skincare line and extends distribution to several high-end retailers
  • Valeant receives FDA approval for, and launches, Zelapar®, for Parkinson’s Disease

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • Biovail announces $27.6 million expansion of its Steinbach, Manitoba manufacturing facility
  • Valeant completes public offering of 7.2 million shares
  • Valeant further expands its neurology franchise, acquiring Xcel Pharmaceuticals

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • Valeant acquires Amarin Pharmaceuticals, expanding its specialty neurology platform
  • Biovail receives regulatory approval for several pharmaceutical products indicated for treatment of angina, hypertension, and acute and chronic pain

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • FDA approves anti-depressant Wellbutrin XL®
  • Valeant Pharmaceuticals International is formed when ICN changes its name
  • Under the ticker symbol VRX, Valeant Pharmaceuticals begins trading on the New York Stock Exchange

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • ICN divests its biomedical subsidiary, along with operations in Russia, Hungary and the Czech Republic
  • Biovail acquires Canadian rights to Wellbutrin SR®

In 2010, Valeant and Canadian specialty pharmaceutical company Biovail merged, with the new company retaining the Valeant name. As a result of the transaction, this timeline includes highlights from the histories of Valeant and Biovail before the two companies combined.

  • ICN Pharmaceuticals, ICN Biomedicals, SPI Pharmaceuticals and Viratek merge into a single, worldwide pharmaceutical company: ICN Pharmaceuticals, Inc.
  • ICN stocks trade for the first time on the New York Stock Exchange
  • Biovail and GlaxoSmithKline sign licensing agreement for Wellbutrin®
  • Biovail is included in the Toronto Stock Exchange 35 index, a list of Canada’s 35 largest corporations
  • Making its first foray into the U.S. market, Biovail acquires DJ Pharma
  • Biovail opens a manufacturing facility in Steinbach, Manitoba